<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349995</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10278</org_study_id>
    <nct_id>NCT04349995</nct_id>
  </id_info>
  <brief_title>Amplatzer PFO Occluder Post-marketing Surveillance Study</brief_title>
  <acronym>PFO PMS Jpn</acronym>
  <official_title>Amplatzer PFO Occluder Post-marketing Surveillance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Amplatzer PFO Occluder post-marketing clinical use surveillance study is
      to observe the frequency, type and degree of adverse device effects and adverse events in
      order to assure the safety of the new medical device, and to collect safety and efficacy
      information for evaluating the results of the clinical use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the Ministerial Ordinance on Good Post-marketing Study Practice for Medical Device,
      the Surveillance will register patients with patent foramen ovale (PFO) who have experienced
      a PFO-related cryptogenic cerebral infarction (including diagnosed paradoxical cerebral
      embolism) or transient ischemic attack (determined by positive head imaging such as DWI) in
      whom an Amplatzer PFO Occluder implant was attempted (Marketing Approval No.
      30100BZX00024000, date May 28, 2019, hereinafter referred to as &quot;PFO occluder&quot;).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">May 28, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>device- or procedure related SAE rate</measure>
    <time_frame>up to 30 Days</time_frame>
    <description>device- or procedure related serious adverse events (SAEs) through 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PE, DVT and ischemic stroke and atrial fibrillation rate</measure>
    <time_frame>beyond 30 days through 3 years</time_frame>
    <description>rate of pulmonary embolism (PE), deep vein thrombosis (DVT), ischemic stroke and atrial fibrillation beyond 30 days through 3 years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effective PFO closure</measure>
    <time_frame>At 1 year</time_frame>
    <description>Effective closure of the PFO at 1 year</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>PFO - Patent Foramen Ovale</condition>
  <arm_group>
    <arm_group_label>Amplatzer PFO Occluder</arm_group_label>
    <description>Percutaneous PFO Closure using Amplatzer PFO occluder</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amplatzer PFO Occluder</intervention_name>
    <description>Percutaneous PFO closure using Amplatzer PFO Occluder</description>
    <arm_group_label>Amplatzer PFO Occluder</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be considered registered upon insertion of the Amplatzer PFO Occluder
        delivery system into the body
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refer to Amplatzer PFO occluder IFU

        Exclusion Criteria:

          -  Refer to Amplatzer PFO occluder IFU
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Etsuro Okamoto</last_name>
    <phone>+81-3-4560-0730</phone>
    <email>etsuro.okamoto@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abbott Medical Japan LLC</name>
      <address>
        <city>Mita</city>
        <state>Minato</state>
        <zip>108-6304</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etsuro Okamoto</last_name>
      <phone>+81-3-4560-0730</phone>
      <email>etsuro.okamoto@abbott.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

